Brokers Set Expectations for Innate Pharma FY2030 Earnings

Key Points

• HC Wainwright projects Innate Pharma will earn $0.42 per share in FY2030 and rates the stock Buy with a $5.00 price target; MarketBeat shows a consensus rating of Moderate Buy and a $5.00 consensus target.
• Innate Pharma reported Q4 results of ($0.18) EPS and $2.41 million in revenue, and its shares trade around $1.45 with a 52‑week range of $1.17–$2.63 (50‑day $1.55, 200‑day $1.77).
• The clinical‑stage biotech is developing antibody therapies including lead program monalizumab (in collaboration with AstraZeneca); institutional ownership is very low (~0.16%) although Millennium, Jane Street and OLD Mission initiated small positions recently.

Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA - Free Report) - Equities researchers at HC Wainwright issued their FY2030 EPS estimates for Innate Pharma in a research report issued on Tuesday, April 7th. HC Wainwright analyst S. Ramakanth expects that the company will post earnings of $0.42 per share for the year. HC Wainwright currently has a "Buy" rating and a $5.00 price target on the stock.

A number of other research analysts have also recently issued reports on the stock. Weiss Ratings restated a "sell (e+)" rating on shares of Innate Pharma in a report on Thursday, January 22nd. BTIG Research began coverage on shares of Innate Pharma in a report on Thursday, March 12th. They set a "buy" rating and a $8.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $5.00.

Innate Pharma Stock Performance

Shares of NASDAQ IPHA opened at $1.45 on Thursday. The firm has a 50 day moving average price of $1.55 and a 200 day moving average price of $1.77. Innate Pharma has a 52-week low of $1.17 and a 52-week high of $2.63.

Innate Pharma (NASDAQ:IPHA - Get Free Report) last posted its quarterly earnings results on Saturday, February 14th. The company reported ($0.18) earnings per share for the quarter. The company had revenue of $2.41 million for the quarter.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in IPHA. Millennium Management LLC acquired a new position in shares of Innate Pharma in the fourth quarter valued at approximately $36,000. OLD Mission Capital LLC acquired a new position in shares of Innate Pharma in the fourth quarter valued at approximately $50,000. Finally, Jane Street Group LLC acquired a new position in shares of Innate Pharma in the fourth quarter valued at approximately $162,000. Institutional investors and hedge funds own 0.16% of the company's stock.

About Innate Pharma

Innate Pharma SA is a clinical-stage biotechnology company specializing in the discovery and development of antibody-based therapies that harness the body's innate immune system to combat cancer. Founded in 1999 and headquartered in Marseille, France, the company pioneers novel monoclonal antibodies designed to activate natural killer cells and macrophages, offering a complementary approach to existing immuno-oncology treatments.

The company's lead program, monalizumab, targets the NKG2A immune checkpoint receptor and is being developed in collaboration with AstraZeneca.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.